首页    期刊浏览 2024年12月01日 星期日
登录注册

文章基本信息

  • 标题:Serum Level of Growth-Associated Protein 43 Is Associated with First-Episode Schizophrenia Patients without Antipsychotic Drugs Treatment
  • 本地全文:下载
  • 作者:Libin Xiao ; Xiaowei Tang ; Xiuxiu Hu
  • 期刊名称:Computational Intelligence and Neuroscience
  • 印刷版ISSN:1687-5265
  • 电子版ISSN:1687-5273
  • 出版年度:2022
  • 卷号:2022
  • DOI:10.1155/2022/4719271
  • 语种:English
  • 出版社:Hindawi Publishing Corporation
  • 摘要:Nerve growth-associated protein 43 (GAP43) is closely related to neural development, axon regeneration, and synaptic reconstruction and is one of the important markers of neuronal damage. Therefore, in our study, enzyme-linked immunosorbent assay (ELISA) was used to analyze the serum level of GAP43 protein in schizophrenia patients (n = 188), healthy controls (n = 200), and bipolar disorder patients (n = 200). The positive and negative syndrome scale (PANSS) was used to evaluate the mental status of schizophrenia patients, and the Scale of Social Function in Psychosis Inpatients (SSPI) was used to evaluate the social function of schizophrenia patients. According to this study, we found the serum GAP43 level was significantly higher in schizophrenia patients than in bipolar disorder patients, while serum GAP43 levels in bipolar disorder patients were significantly higher than those in control group. When the cut-off value was set as 2.328 ng/mL, the area under the curve (AUC) of serum GAP43 was 0.7795 (95% CI: 0.7431–0.8158) for diagnosis of schizophrenia. The sensitivity and specificity were 92.02% and 65.25%, respectively. However, no correlation between serum GAP43 and the total scores of PANSS scale in schizophrenia patients as well as between serum GAP43 level and SSPI were observed. Therefore, we believe that GAP43 may be a potential diagnostic marker for schizophrenia.
国家哲学社会科学文献中心版权所有